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Objective: To assess mortality risk and extent of increased length of hospital stay in
patients with burn injury with preexisting liver disease. Methods: Records of 31,338
adults who were admitted with burns to 70 burn centers were reviewed from the Amer-
ican Burn Association National Burn Repository. Demographics, percentage burn, and
medical characteristics of 180 patients with liver disease were compared with all pa-
tients without liver disease and to a propensity score–matched sample of 180 patients
without liver disease. Risk of mortality as well as lengths of both intensive care and
total stay were compared after matching for demographics, burn injury, and preexisting
medical conditions. Results: Patients with liver disease were significantly more likely
to have a history of a number of medical comorbidities, including alcohol abuse, drug
abuse, a psychiatric diagnosis, chronic pulmonary disease, hypertension, and diabetes.
Patients with liver disease were significantly more likely to die in the hospital (27.2%
vs 6.9%, odds ratio = 5.0, 95% confidence interval = 3.6–7.0, P < .01), and this held
even when compared with a propensity score–matched group of patients without liver
disease, but with similar demographics, burn injury, and medical profiles. Lengths of
both intensive care and total hospital stay were 122.5% (P < .01) and 86.7% (P < .01)
longer, respectively, among patients with liver disease than among all other patients.
In a matched sample, lengths of both intensive care and total stays were longer, albeit
not significantly so (41.6%, P = .12; 35.5%, P = .07). Conclusions: Liver impairment
worsens the prognosis in patients with thermal injury.
Several preexisting medical conditions have been linked to increased mortality risk
among burn patients. No studies, however, have assessed the impact of liver disease in
the burn population. In addition, no statistical data exist to examine the effects of liver
impairment on burn mortality or the relationship between this disease and length of care.
Aw hole range of disorders of the liver, including portal hypertension, ascites, hepatic
encephalopathy, jaundice, hepatorenal syndrome, and hepatitis, may influence the outcome
following a burn injury. All have the potential to be life-threatening. We analyzed data
from the American Burn Association National Burn Repository (ABA-NBR) to address
specifically the effects of hepatic impairment on burn mortality and length of stay.
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Table 1. TheChild-Pughclassiﬁcationforassessingtheseverityofliver
cirrhosis∗
Score 1 2 3
Total bilirubin, mg/dL <2.0 2.0–3.0 >3.0
Albumin, g/dL >3.5 2.8–3.5 <2.8
Prothrombin time (prolonged), s, or <4 4–6 >6
prothrombin time INR <1.7 1.7–2.3 >2.3
Encephalopathy None Mild Moderate
Ascites None Mild Moderate
∗The individual scores are summed and then grouped as follows: A = 5–6; B = 7–9; and
C = 10–15. A “C” classification forecasts a survival of less than 12 months. INR indicates
international normalized ratio.
Our experience with patients with cirrhosis in the trauma and general surgical popula-
tions indicates increased risk of mortality with liver failure as predicted by the Child-Pugh
classification. In a comprehensive analysis of 100 patients with cirrhosis undergoing ab-
dominal operations, Garrison et al1 found that emergency operations were associated with
more than a 5-fold increase (57% vs 10%) in mortality rate than in patients having elective
operations. Doberneck et al2 reported similar observations, whereby a 4-fold increase in
mortality rate following emergency procedures (45% vs 11%) was obtained. Garrison et al1
found that when patients were segregated into three groups according to the Child-Pugh
classification, the mortality rates were 10% in class A, 31% in class B, and 76% in class C
patients (Table 1). Age, burn size, and inhalation injury are robust predictors of mortality
and of hospital stay following an acute burn injury.3−6
METHODS
Patient sample, variables, and outcome measures
Data were extracted from the ABA-NBR database for all adult patients aged 18 to 89 years
whow ere admitted to 70 burn centers across the United States with thermal injuries (flame,
contact, or scald) from 1995 through 2005. Patient data in the ABA-NBR included age,
sex, race, year of injury, hospital admission status (eg, direct admission or transfer), the
etiology and circumstances of the burn injury, mortality status and cause, percentage total
body surface area (TBSA) burned, percentage TBSA burned second degree, percentage
TBSA burned third degree, the presence or absence of an inhalation injury, and preexisting
medical conditions.
Inthisstudy,patientswithandwithoutliverdiseasewerecomparedandmatchedonthe
basis of demographics, burn injury, and preexisting medical conditions. Liver disease and
otherpreexistingconditionsweredefinedasclinicalconditionsthatpredatedtheburninjury
andadmissiontothehospitalandthatcouldreasonablybeexpectedtoimpactmortalityand
course of treatment.7 There was no limit to the number of different medical comorbidities
that could be coded in the database for a given patient. Diagnosis codes for liver disease
and other relevant preexisting medical conditions were selected from those included in
the Deyo adaptation8 of the Charlson Index9 and the Elixhauser method of comorbidity
measurement.7 The list of preexisting medical conditions included in this study and their
ICD-9 codes are shown in Table 2.
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Table 2. ICD-9-CM codes of comorbidities
Comorbidity ICD-9-CM codes
Alcohol abuse 291.1, 291.2, 291.5, 291.8, 291.9, 303.90–303.93, 305.00–305.03, V113
Cardiac arrhythmias 426.10, 426.11, 426.13, 426.2–426.53, 426.6–426.89, 427.0, 427.2,
427.31, 427.60, 427.9, 785.0, V45.0, V53.3
Chronic pulmonary disease 490–496, 500–505, 506.4
Congestive heart failure 398.91, 402.11, 402.91, 404.11, 404.13, 404.91, 404.93, 428.0–428.9
Dementia 290–290.9
Diabetes 250–250.33, 250.40–250.73, 250.90–250.93
Drug abuse 292.0, 292.82–292.89, 292.9, 304.00–304.93, 305.20–305.93
HIV/AIDS∗ 042
Hypertension 401.1, 401.9, 402.10, 402.90, 404.10, 404.90, 405.11, 405.19, 405.91,
405.99
Hypothyroidism 243–244.2, 244.8, 244.9
Cerebrovascular disease 438.0
Liver disease 070.32, 070.33, 070.54, 456.0, 456.1, 456.20, 456.21, 571.0, 571.2,
571.3, 571.40–571.49, 571.5, 571.6, 571.8, 571.9, 572.2–572.8, V42.7
Metastatic cancer† 196.0–199.1
Nonmetastatic malignancy† 140–172.9, 174–195.8, 200–208.9, 238.6, 273.3, V10.00–V10.9
Obesity 278.0
Old myocardial infarction 412.0
Other neurological disorders 331.9, 332.0, 333.4, 333.5, 334.0–335.9, 340, 341.1–341.9,
345.00–345.11, 345.40–345.51, 345.80–345.91
Paralysis 342.0–342.12, 342.9–344.9
Peptic ulcer disease 531–534.9, V12.71
Peripheral vascular disease 440.0–440.9, 441.2, 441.4, 441.7, 441.9, 443.1–443.9, 447.1, 557.1,
557.9, V43.4
Psychiatric diagnosis 295.0–295.9, 296.0, 296.2–298.9
Pulmonary circulation disorders 416.0–416.9, 417.9
Renal disease 403.11, 403.91, 404.12, 404.92, 582–582.9, 583–583.7, 585, 586,
588–588.9, V42.0, V45.1, V56.0, V56.8
Rheumatologic disease 701.0, 710.0–710.9, 714.0–714.9, 720.0–720.9, 725
Valvular disease 093.20–093.24, 394.0–397.1, 424.0–424.91, 746.3–746.6, V42.2, V43.3
∗Excludes asymptomatic HIV infection status.
†If both solid tumor without metastatis and metastatic cancer are present, only metastatic cancer is counted.
Patients aged 90 and older were not included in the study because their actual ages
were not entered into the dataset owing to patient privacy regulations. Patient records with
missing data points were excluded from the analysis. In addition, all duplicate cases were
removed from the dataset. A more complete description of the ABA-NBR database is
provided elsewhere.10 Outcome measures were in-hospital death and, among survivors,
lengths of both total hospital stay and intensive care stay.
Statistical analysis
Statistical significance was defined as a probability value less than 0.05. χ2 and Fisher’s
exact tests were used to compare categorical variables, and 2-tailed t tests were used to
compare continuous demographic and clinical variables between patients with liver disease
and patients with no diagnosis of liver disease.
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To adjust for differences in demographics, burn injury, and clinical characteristics
of patients with liver disease and patients with no diagnosis of liver disease, we used a
propensity score approach to generate a set of matched cases.11,12 The propensity score is a
measureofthelikelihoodthatapatienthadadiagnosisofliverdiseaseonthebasisofrelevant
demographics, burn injury, and clinical variables. This approach reduces many covariates
to a single variable, the propensity score. Since patients with similar propensity scores have
similarcharacteristics,oncematched,mortalityandlengthofstaycanbecomparedbetween
patients with a diagnosis of liver disease and patients without a history of liver disease.
A stepwise logistic regression approach with P <. 50 as the limit for variable entry
was used to model the likelihood that patients had a diagnosis of liver disease on the basis
of demographics, burn injury, and clinical variables. A propensity score was generated
for each patient, and each patient who had a diagnosis of liver disease was matched with a
patientwiththeclosestpossiblepropensityscorewhodidnothaveahistoryofliverdisease.
The maximum allowable difference between propensity scores for matching was set at 0.1.
When2ormorepatientswithoutahistoryofliverdiseasehadanidenticalpropensityscore,
the matched patient was chosen randomly.13
Risk for death was assessed by calculating odds ratios for patients diagnosed with
liver disease compared with propensity score–matched patients without a diagnosis of
liver disease. Total length of hospital stay and the length of intensive care were positively
skewed, and thus compared between patients with liver disease and matched controls using
a nonparametric statistical test, the Wilcoxon rank sum test. All analyses were performed
with SPSS, Version 14.0 (Chicago, Ill). Data are reported in the text as means (± standard
deviation) or as odds ratios with 95% confidence intervals.
RESULTS
Patient characteristics
A total of 31,338 adult patients aged 18 to 89 were admitted to 70 burn centers. The mean
age of adult patients in the ABA-NBR was 43.4 ± 17.2 years (range = 18–89 years);
72.8% of patients were men, and 65.7% were white. The mean percentage TBSA burned
was 13.1% ± 16.2% (range = 0%–100%), and 13.2% of the sample incurred an inhalation
injury. Table 2 shows the diagnoses of patients classified as having liver disease. The most
common diagnoses were hepatitis of any variety (49.4%) and alcoholic cirrhosis (34.4%).
Baseline demographics, burn injury, and clinical characteristics of the patients by
hepatic disease status are shown in Table 3. More than 50% of patients with liver dis-
ease also had a history of alcohol abuse and almost 20% had a history of drug abuse,
compared with only 5.5% and 3.2%, respectively, in patients without a diagnosis of liver
disease. Patients with hepatic insufficiency were also significantly more likely to have di-
agnoses of cardiac arrhythmias, cerebrovascular disease, chronic pulmonary disease, con-
gestive heart failure, diabetes mellitus, HIV/AIDS, hypertension, and hypothyroidism. In
addition, patients with liver disease were significantly older and had more extensive burn
injuries.
The final propensity score model for matching patients included 12 individual pre-
dictor variables (age, TBSA burned third degree, congestive heart failure, hypertension,
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Table 3. Diagnoses of patients with liver disease
Number (%)* of patients
Diagnosis with liver disease
070.32 Hepatitis B 11 (6.1)
070.54 Hepatitis C 66 (36.7)
456.0, 456.1 Esophageal varices 16 (8.9)
571.2, 571.3 Alcoholic cirrhosis 62 (34.4)
571.3, 571.4–571.49 Chronic hepatitis 16 (8.9)
571.5, 571.8, 571.9 Chronic liver disease, no mention of alcohol 25 (13.9)
572.2 Hepatic coma 6 (3.3)
572.3 Portal hypertension 7 (3.9)
572.4 Hepatorenal syndrome 5 (2.8)
572.8 Other sequelae of chronic liver disease 16 (8.9)
∗Percentages do not add to 100% owing to multiple diagnoses related to liver disease in some patients.
neurological disorder, chronic pulmonary disease, diabetes mellitus, peptic ulcer disease,
obesity,alcoholabuse,apsychiatricdiagnosis,andHIV/AIDS)and10interactionswithage
(congestive heart failure, neurological disease, chronic pulmonary disease, diabetes melli-
tus, peptic ulcer disease, obesity, alcohol abuse, drug abuse, a psychiatric diagnosis, and
HIV/AIDS). The c-statistic for the propensity score model was 0.88, indicating adequate
discrimination. Collinearity analysis showed that the variables included in the propensity
scorewerenothighlycorrelated;thehighestbivariatecorrelationbetweenanytwovariables
was 0.35. All 180 patients with a diagnosis of liver disease were successfully matched: 85
on 5 or more digits of the propensity score, 65 on 4 digits, 21 on 3 digits, 8 on 2 digits, and
1o n1digit. After propensity score matching, there were no significant difference between
the 180 patients with liver disease and the comparison group of 180 patients with no history
of liver disease (Table 4).
In-hospital mortality and length of stay
Priortoadjustmentthroughmatching,patientswithadiagnosisofliverdiseasewerealmost
4 times as likely to die from the burn injury than patients without liver disease (27.2%
vs 6.9%, P < .01). Even after matching across age, sex, burn injury severity, and other
preexisting medical conditions, mortality rates were significantly higher among patients
with liver disease than among matched controls (15.0%, P < .01). Mean length of intensive
care was more than double for patients with liver disease (10.6 days) than for all patients
without liver disease (4.5 days, P < .01), and total stay was almost 90% longer (18.8 days
vs 12.9 days, P < .01). After matching, ICU stay was 41.6% longer for patients with live
disease (P = .12) and total stay was 35.5% longer (P = .07) (Table 5).
DISCUSSION
This is the first study to examine the association of the presence of liver disease with
mortality risk and length of stay among patients with burn injury. Patients with a diagnosis
of liver disease were significantly more likely than all other patients to die and required
significantlylongerlengthsofbothintensivecareandtotalstay.Evenwhencomparedwitha
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Table 4. Baseline demographic and clinical characteristics∗
Prepropensity Postpropensity
score matching score matching
Liver disease No liver disease No liver disease
(n = 180) (N = 31,158) P (n = 180) P
Age, mean ± SD, y 51.4 ± 11.8 43.3 ± 17.3 <.01 50.2 ± 14.2 .38
Total TBSA, mean ± SD, % 17.1 ± 16.9 13.1 ± 16.1 <.01 17.1 ± 18.7 .99
FT-TBSA, mean ± SD, % 9.6 ± 15.8 5.1 ± 13.1 <.01 10.0 ± 17.12 .83
Inhalation injury 45 (25.0) 4,101 (13.2) <.01 40 (22.2) .54
Fire/flame or inhalation 136 (75.6) 2,0125 (64.6) <.01 138 (76.7) .81
Male gender 127 (70.6) 22,698 (72.8) .49 116 (64.4) .22
White 116 (66.3) 19,844 (65.7) .87 115 (66.9) .91
Alcohol abuse 94 (52.2) 1,720 (5.5) <.01 101 (56.1) .46
Cardiac arrhythmias 10 (5.6) 610 (2.0) <.01 7 (3.9) .46
Cerebrovascular disease 3 (1.7) 104 (0.3) .02 1 (0.6) .31
Chronic pulmonary disease 43 (23.9) 1,560 (5.0) <.01 43 (23.9) 1.00
Congestive heart failure 11 (6.1) 476 (1.5) <.01 8 (4.4) .48
Dementia 0 (0.0) 87 (0.3) .61 0 (0.0) 1.00
Diabetes mellitus 23 (12.8) 1,342 (4.3) <.01 21 (11.7) .75
Drug abuse 34 (18.9) 987 (3.2) <.01 29 (16.1) .49
HIV/AIDS 7 (3.9) 61 (0.2) <.01 5 (2.8) .56
Hypertension 45 (25.0) 2,949 (9.5) <.01 42 (23.3) .71
Hypothyroidism 6 (3.3) 268 (0.9) <.01 6 (3.3) 1.00
Metastatic cancer 0 (0.0) 46 (0.1) .77 1 (0.6) .50
Nonmetastatic malignancy 0 (0.0) 137 (0.4) .45 2 (1.1) .25
Obesity 5 (2.8) 376 (1.2) .07 3 (1.7) .36
Old myocardial infarction 5 (2.8) 259 (0.8) .02 7 (3.9) .56
Other neurological disorders 8 (4.4) 479 (1.5) <.01 8 (4.4) 1.00
Paralysis 1 (0.6) 214 (0.7) .65 0 (0.0) .50
Peptic ulcer disease 9 (5.0) 120 (0.4) <.01 6 (3.3) .43
Peripheral vascular disease 3 (1.7) 190 (0.6) .10 2 (1.1) .50
Psychiatric diagnosis 22 (12.2) 874 (2.8) <.01 27 (15.0) .44
Pulmonary circulation disorders 0 (0.0) 54 (0.2) .73 1 (0.6) .50
Renal disease 4 (2.2) 173 (0.6)) .02 4 (2.2) 1.00
Rheumatologic disease 3 (1.7) 125 (0.4) .03 1 (0.6) .31
Valvular disease 0 (0.0) 107 (0.3) .51 2 (1.1) .50
∗Values given are number (percentage) unless otherwise indicated. TBSA indicates total body surface area.
setofmatchedpatientswithoutliverdisease,butwhoweresimilarintermsofdemographics,
burninjury,andmedicalprofiles,patientswithhepaticdiseaseweresignificantlymorelikely
to die from their burn injuries. Although not statistically significant, time in intensive care
andtotaltimeinthehospitalwerealsosubstantiallylongeramongpatientswithliverdisease
than among matched controls.
Alteration of liver function tests is extremely common following major burns. An
incidenceashighas50%hasbeendescribedwhenthereistransientelevationoftheaspartate
aminotransferase, alanine aminotransferase, and particularly the alkaline phosphatase. The
precise etiology of these changes is not known, but they usually are benign in character and
resolve spontaneously. Elevation of the serum bilirubin is somewhat less common but of
more serious consequence. Patients who show severe and persistent derangements of the
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Table 5. Mortality and length of stay of patients with liver disease compared with all patients with
no liver disease and with a matched sample of patients with no liver disease
No liver disease Prematch Postmatch
Prematch Postmatch Liver disease Odds ratio Odds ratio
(N = 31,158) (n = 180) (n = 180) (95% CI) P (95% CI) P
Mortality, n(%) 2154 (6.9) 27 (15.0) 49 (27.2) 5.0 (3.6–7.0)  .01 2.1 (1.3–3.6) <.01
No liver disease
after matching Liver disease % Increase % Increase
(n = 180) (n = 180) prematch P postmatch P
Length of stay
ICU, days (SD) 4.5 (13.9) 7.5 (16.9) 10.6 (21.4) 122.5  .01 41.6 .12
Total, days (SD) 12.9 (19.3) 18.8 (21.5) 25.4 (28.6) 86.7 <.01 35.5 .07
liver enzymes, including elevation of bilirubin, usually have some associated complication
of their burns, such as burn wound sepsis, and in these patients, the prognosis is guarded.
Effect of hepatic failure on burn pathophysiology
The liver plays an important role in the body’s response to thermal injury. It is the prin-
cipal organ responsible for producing acute-phase proteins and modulating the systemic
inflammatory response.14 Following thermal injury, the acute-phase response brings about
the activation of the coagulation and complement cascades, granulocytes, and monocytes/
macrophagesaswellasplatelets,15−19andinducesthelivertosynthesizeandreleaseproteins
that exert effects on a variety of tissues.20 After major trauma, such as a severe burn, hep-
aticproteinsynthesisshiftsfromhepaticconstitutiveproteins,suchasalbumin,prealbumin,
transferrin, and retinol-binding protein, to acute phase proteins,14 which serve as mediators
of the inflammatory process, function as transport proteins, and participate in burn wound
healing.21,22 Jeschke et al23 recently demonstrated that the acute-phase response persists
for longer duration than previously thought, which suggests that any compromise in liver
function as seen in patients with chronic liver disease has both short-term and long-term
detrimental effects on the body’s ability to respond to burn injury.
Impaired glucose tolerance
The liver helps maintain glucose homeostasis by synthesizing glycogen and generating glu-
cose from precursors. Glucose metabolism in patients with severe burn is almost always
abnormal. Patients that are victims of sepsis, burn, or trauma commonly enter a hyper-
metabolic stress state that is associated with changes in carbohydrate metabolism, such
as enhanced peripheral glucose uptake and utilization, hyperlactatemia, increased glucose
production, depressed glycogenesis, glucose intolerance, and insulin resistance.24 These
abnormalities would likely be exaggerated in patients with liver disease, as altered glucose
tolerance is known to occur in alcoholic chronic liver disease, nonalcoholic fatty liver,
chronic hepatitis C, and portal hypertension.25 The impaired metabolism of glucose is
aggravated with the progression of chronic hepatitis to liver cirrhosis.25 In patients with
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cirrhosis, the prevalence of impaired glucose tolerance is estimated to be about 60% to
80%, whereas that of overt diabetes is about 7% to 15%.25
Reduced absorption of fat-soluble vitamins and nutrients
Theliverisvitaltotheuptake,storage,andmobilizationofvitamins,whichplayasignificant
role in wound healing, energy, metabolism, inflammation, and antioxidant activity.14 The
fat-soluble vitamins, Vitamins A, E, D, and K, the absorption of which are dependent
on bile salts, are the most important in relation to thermal injury.14 Af ailure to secrete
bile leads to poor solubilization of dietary lipids and the fat-soluble vitamins, resulting in
malabsorptionanddeficiencystates,respectively.26 Malnutritioniscommoninpatientswith
advancedcirrhosisandisassociatedwithincreasedinfectionrisk,multiorgancomplications,
hemorrhage from esophageal varices, posttransplant infection, prolonged hospitalization,
andmortality.27Postburnhypermetabolismfrequentlycausesavitamindeficiency,requiring
supplementation to facilitate recovery.28 These data suggest that poor nutritional status
arising from chronic liver disease prior to burn injury could complicate the repletion of
essential nutrients in the postburn period and directly increase the risks of morbidity and
mortality following burn injury.
Drug metabolism and detoxiﬁcation
Many liver diseases significantly compromise drug metabolism by impairing cytochrome
P450andotherimportanthepaticenzymes.Asaresultofthisslowedmetabolism,thelevels
of the active forms of many drugs may be significantly higher than intended, and thereby
cause toxic effects. Conventional wisdom dictates that the doses of many drugs be low-
ered for individuals with hepatic disease. However, burn injury induces many pathological
changes in the human body, leading to alterations in pharmacokinetic parameters such as
bioavailability, protein binding, volume of distribution (Vd), and clearance.29 The pharma-
cokinetic parameters following burn injury vary between the acute phase of injury and the
second hypermetabolic phase beyond the initial 48 hours of thermal injury.30 Decreased
blood flow to tissues during the resuscitation phase reduces the rate of drug elimination
by the kidneys and liver.30 During the hypermetabolic phase, increased blood flow may
increase enough clearance of some of the drugs in order to require higher dosages than
usual.30 The free fraction of a drug in plasma may be increased or decreased depending
on its protein-binding characteristics.29,31 In addition, thermal injury has a direct impact
on hepatic metabolism: the rate of phase I metabolism decreases, which is thought to be
related to the oxygen-derived free radicals released during the course of injury, whereas
phase II metabolism is unimpaired and may possibly increase.30 Other liver functions, such
as protein synthesis, can also be disrupted by thermal injury.30 Given the extreme interpa-
tient variability in drug handling among patients with burn injury, particularly with regards
to antibiotics,32 preexisting liver disease can further complicate the dosing of drugs admin-
istered in the postburn period. Weinbren cautions that some patients may be exposed to
subtherapeutic levels of antibiotics due to its rapid clearance even if the dose provided
is perceived to be sufficiently in excess of requirement.32 Weinbren’s experience with
antibiotics in patients with burn injury suggests that, in general, one must balance the
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need to increase dosing to achieve therapeutic drug levels with the need to avoid toxicity in
a patient with chronic liver disease.
In addition, the capacity of liver to detoxify exogenous and endogenous chemicals,
foreign molecules, and hormones is limited by chronic liver disease. Clearance of bacteria
by Kupffer cells of the liver normally helps prevent gut-derived bacteria from entering the
systemic circulation. Loss of this function in liver disease as a result of portal-to-systemic
shunting may help explain why patients with severe liver disease are more susceptible to
developing systemic infections and septic complications.33 In their review article, Gosain
andGamelli34 statethatthereisalossofphysicalbarrierfunctioninthegastrointestinaltract
after burn injury, allowing translocation of bacteria and endotoxin to the portal circulation,
whichcanleadtothedevelopmentofmultiple-organfailure.Mostburn-relateddeaths(54%)
inmodernburnunitsoccurbecauseofsepticshockandorgandysfunction.35 Thelossofthe
liver’s ability to clear gut-derived bacteria most likely increases the risk of postburn sepsis
in these patients.
Coagulation deﬁciency
Thrombotic and fibrinolytic mechanisms are activated after burn injury, with the extent
of activation correlated to the severity of the thermal injury.14 Although much attention
has been placed on increased thrombogenicity in patients with burn injury resulting from
a decrease in antithrombin III, protein C, and protein S levels, complications of hyperco-
agulability in such patients are rare.36 Barret and Gomez37 have also suggested that the
true incidence of disseminated intravascular coagulation, documented in up to 30% of ex-
amined cases by Wells et al, is much lower than previously reported. In contrast, patients
with burn injury with preexisting liver disease have increased risk of hemorrhagic com-
plications. The liver produces most of the factors involved in coagulation and fibrinolysis
that helps maintain the balance between thrombin deposition and removal.38 Patients with
cirrhosis frequently experience hemostatic disorders caused by abnormalities of platelet
number and/or function, increased fibrinolysis, and deficient synthesis of clotting factors.38
Clotting factor deficiencies develop with the loss of functioning liver paranchymal cells,
withearlydeficitsintheVitaminK–dependentfactors(II,VII,IX,X,proteinS,andprotein
C).38 The loss of factor VII significantly interferes with the function of the extrinsic coag-
ulation cascade.38 Hemorrhagic complication is a major concern in patients with cirrhosis
undergoing surgical interventions39 and must be considered when preparing a patient with
burn injury with preexisting liver disease for surgery.
Traditionally, patients with liver disease have been considered to be at high risk for
mortality, particularly in the context of patients with liver failure. It is not surprising that
individuals with hepatic insufficiency are at an increased likelihood of dying from the burn
injury in comparison with those without liver disease. These patients tend to have multiple
medical problems coexisting with and stemming from their damaged liver. Two factors that
often contribute to mortality are the propensity to bleed because of coagulopathies and
ascites, which often lead to sepsis. The physiologic stress placed on patients with burn
injury along with their hypermetabolic demands may lower the threshold for survival.
There are limitations that should be taken into consideration while interpreting the
results from this study. The data are from a large registry and are to some degree flawed in
theirabilitytocapturepatientillnessseverity.Patientcomorbidityandinjuryvariables,such
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as TBSA burned or the presence or absence of inhalation injury, were extracted by chart
review and diagnoses were documented with ICD-9 coding rather than by more precise
methods. An additional limitation is that differences in mortality across burn care centers
related to differences in standard burn management or differences in patient characteristics
were not explicitly incorporated into the analysis. The ABA-NBR does not include data on
important factors that may differ across centers, such as time from burn to admission or
fluid resuscitation. To the extent that a large number of burn centers were included in this
study,however,itisnotunreasonabletothinkthattheresultsofthisstudyarerepresentative
of typical patterns across burn centers in the United States.
Insummary,wefoundthatpatientswithadiagnosisofliverdiseaseareatsubstantially
greaterriskformortalitysubsequenttoburninjury,evenaftermatchingonkeydemograph-
ics, burn injury, and medical variables. In addition, patients with liver disease who survive
their injuries tend to require longer hospital stays than their matched counterparts without
liver disease.
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